Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.

导出原文传递

翻译打印收藏纠错

作者： Elizabeth A,Punnoose ^[1] ; Joel D,Leverson ^[2] ; Franklin,Peale ^[3] ; Erwin R,Boghaert ^[4] ; Lisa D,Belmont ^[5] ; Nguyen,Tan ^[5] ; Amy,Young ^[6] ; Michael,Mitten ^[4] ; Ellen,Ingalla ^[6] ; Walter C,Darbonne ^[1] ; Anatol,Oleksijew ^[4] ; Paul,Tapang ^[4] ; Peng,Yue ^[5] ; Jason,Oeh ^[6] ; Leslie,Lee ^[6] ; Sophie,Maiga ^[7] ; Wayne J,Fairbrother ^[8] ; Martine,Amiot ^[7] ; Andrew J,Souers ^[4] ; Deepak,Sampath ^[9]

作者单位： Oncology Biomarkers, Genentech, South San Francisco, California. ^[1] Oncology Development, AbbVie, Inc, North Chicago, Illinois. ^[2] Research Pathology, Genentech, South San Francisco, California. ^[3] Oncology Discovery, AbbVie, Inc, North Chicago, Illinois. ^[4] Discovery Oncology, Genentech, South San Francisco, California. ^[5] Translational Oncology, Genentech, South San Francisco, California. ^[6] INSERM UMR892, CNRS UMR6299, University of Nantes, Nantes, France. ^[7] Early Discovery Biochemistry, Genentech, South San Francisco, California. ^[8] Translational Oncology, Genentech, South San Francisco, California. dsampath@gene.com. ^[9]